GCP
AGRX

GSA Capital Partners’s Agile Therapeutics AGRX Stock Holding History

GSA Capital Partners’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-367
Closed -$358K – 1956
2021
Q4 		$358K Buy
367
+74
+25% +$104K 0.05% 817
2021
Q3 		$564K Buy
293
+107
+58% +$242K 0.06% 634
2021
Q2 		$495K Buy
186
+116
+166% +$382K 0.06% 635
2021
Q1 		$291K Buy
+70
New +$378K 0.05% 662
2020
Q4 		– Sell
-114
Closed -$693K – 1712
2020
Q3 		$693K Buy
+114
New +$653K 0.12% 237

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSA Capital Partners's AGRX Position: Q1 2022 in Review

GSA Capital Partners sold out of Agile Therapeutics (AGRX) in Q1 2022, closing a stake of 367 shares — an estimated $358K sold.

GSA Capital Partners first reported a position in AGRX in Q3 2020 and held it in 5 quarters. The position peaked at $693K in Q3 2020. 36 funds tracked by Wall St. Rank hold AGRX as of Q1 2022.

  • GSA Capital Partners reported no remaining Agile Therapeutics position as of Q1 2022 after selling out during the quarter.
  • GSA Capital Partners sold 367 Agile Therapeutics shares in Q1 2022, an estimated $358K.
  • GSA Capital Partners first reported a position in Agile Therapeutics in Q3 2020 and held it in 5 quarters.
  • GSA Capital Partners's Agile Therapeutics position peaked at $693K in Q3 2020.
  • 36 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.